Kernal Biologics
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 15
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- kernalbio.com
- Company page
Recent activity at Kernal Biologics
- : Kernal Biologics has been awarded $48 million from ARPA-H to develop in vivo CAR T-cell therapies for hematological cancers. This funding is part of ARPA-H’s EMBODY program, aimed at enhancing immune cell engineering.
- : Kernal Biologics Announces $25M Series A Financing To Advance Its Mrna 2.0 Technology For Oncology
- : Kernal Biologics, Inc.
Employee benefit plans
Kernal Biologics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Kernal Biologics: questions and answers
What does Kernal Biologics do?
Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three
Where is Kernal Biologics headquartered?
Kernal Biologics is headquartered in Cambridge, Massachusetts, United States.
How many employees does Kernal Biologics have?
Kernal Biologics has about 15 employees.
What is the latest news on Kernal Biologics?
On Oct 07, 2025, Kernal Biologics has been awarded $48 million from ARPA-H to develop in vivo CAR T-cell therapies for hematological cancers. This funding is part of ARPA-H’s EMBODY program, aimed at enhancing immune cell engineering.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy